Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab
We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.
Authors
- Iichiro Osawa (ORCID: https://orcid.org/0000-0001-7819-2047)
- Yuji Akiyama (ORCID: https://orcid.org/0000-0001-5658-7419)
- Takuma Tsuzuki Wada (ORCID: https://orcid.org/0000-0002-5527-2965)
- Atsushi Sasaki (ORCID: https://orcid.org/0000-0002-1333-9391)
- Nobuhito Okumura
- Kazuhiro Yokota (ORCID: https://orcid.org/0000-0001-5611-9420)
- K. INOUE (ORCID: https://orcid.org/0009-0002-2468-2141)
- Toshimasa Yamamoto (ORCID: https://orcid.org/0009-0005-1171-6244)
- Mariko Okada
- Toshihide Mimura (ORCID: https://orcid.org/0000-0002-9050-0855)
- Yoshihiko Nakazato
- Takaya Ichimura
- T Ueno
Institutions
- Saitama Medical University Hospital (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2024-12-25
- DOI
- https://doi.org/10.2169/internalmedicine.4503-24
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00